Abstract
Molecular diagnostics is one of the most rapidly growing areas in laboratory medicine. Current applications in dermatology and dermatopathology cover a wide range of conditions, from infectious and inflammatory diseases, to cancer, and inherited skin disorders (genodermatoses). Early molecular tests were developed for diagnosis of systemic hematologic conditions, largely due to the relative ease in accessing specimens (i.e., venapuncture), possibility of abundant tissue for analysis (i.e., whole lymph nodes), and the capabilities of molecular methodologies available at that time (i.e., Southern blot analysis). Technical advances have now permitted the extraction and analysis of template (i.e., DNA and RNA) from both smaller and routinely processed (i.e., formalin-fixed paraffin-embedded [FFPE]) specimens (i.e., skin biopsies), enabling the application of molecular diagnostic testing to other fields, including dermatology. For example, diagnostic and follow-up evaluation of cutaneous diseases with sparse cellular infiltrates (such as many cutaneous lymphoproliferative disorders) is now possible. With the advent of methods for both target and signal amplification of nucleic acids, infectious disease testing has now become the dominant area in molecular diagnostics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maticic M, Poljak M, Lunder T, et al. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol. 2008;22:779–88.
Galan A, McNiff JM, Nam Choi J, et al. Fatal HHV6 infection in an immunocompromised patient presenting with skin involvement. J Cutan Pathol. 2010;37:277–81.
Clinical Laboratory Improvement Act. 2004. http://wwwn.cdc.gov/clia/regs/subpart_m.aspx. Accessed Jan 2010.
American Academy of Dermatology. CLIA Quick Facts. 2003. http://www.aad.org/pm/compliance/clia/facts.html. Accessed Jan 2010.
College of American Pathology. 2010. http://www.cap.org/. Accessed Jan 2010.
International Standards Organization. 2010. http://www.iso.org/. Accessed Jan 2010.
Clinical Laboratory Improvement Act, Health and Human Service approved Board Certifications. 2010. http://www.cms.hhs.gov/CLIA/16_Certification_Boards_Laboratory_Directors.asp#TopOfPage. Accessed Jan 2010.
Chen B, Gagnon M, Shahangian S, et al. Good laboratory practices for molecular genetic testing for heritable diseases and conditions. Morb Mortal Wkly Rep. 2009;58:1–29.
Jennings L, Van Deerlin VM, Gulley M. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133:743–55.
Gulley ML, Braziel R, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;6:852–63.
Maddalena A, Bale S, Das S, et al. Technical standards and guidelines: molecular genetic testing for ultra-rare disorders (URDs). Genet Med. 2005;7:571–83.
Ogino S, Gulley ML, den Dunnen JT, et al. Standard mutation nomenclature in molecular diagnostics. J Mol Diagn. 2007;9:1–6.
HUGO Gene Nomenclature Committee. 2010. www.genenames.org/. Accessed Jan 2010.
United States Patent and Trademark Office Department of Commerce. 2010. http://patft.uspto.gov/. Accessed Jan 2010.
Current Procedural Terminology. CPT 2010. Professional Edition. American Medical Association. ISBN 978-1-60359-119-5.
Weinberg JW, Koestenblatt EK, Jennings MB. Utility of histopathologic analysis in the evaluation of onychomycosis. J Am Podiatr Med Assoc. 2005;95:258–63.
Bergmans AMC, Schouls LM, van der Ent Klaassen MA, et al. Validation of PCR–reverse line blot, a method for rapid detection and identification of nine dermatophyte species in nail, skin and hair samples. Clin Microbiol Infect. 2008;14:778–88.
Thurber SE, Zhang B, Kim YH, et al. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007;57:782–90.
Kardjeva V, Summerbell R, Kantardjiev T, et al. Forty-eight-hour diagnosis of onychomycosis with subtyping of Trichophyton rubrum strains. J Clin Microbiol. 2006;44:1419–27.
Ross LF, Moon MR. Ethical issues in genetic testing of children. Arch Pediatr Adolesc Med. 2000;154:873–9.
Freund CL, Sugarman J. Genetic testing: ethical issues. 2010. http://www.answers.com/topic/genetic-testing-ethical-issues. Accessed Jan 2010.
Office of Biotechnology Activities. Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS). 2010. http://oba.od.nih.gov/SACGHS/sacghs_documents.html. Accessed Jan 2010.
Acknowledgments
I would like to acknowledge the helpful suggestions and comments of Karen Babish.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Payne, D.A. (2011). Regulatory, Legal, Coding, Billing, Reimbursement, and Ethical Considerations for Molecular Diagnostic Testing in Dermatology and Dermatopathology. In: Murphy, M. (eds) Molecular Diagnostics in Dermatology and Dermatopathology. Current Clinical Pathology. Humana Press. https://doi.org/10.1007/978-1-60761-171-4_23
Download citation
DOI: https://doi.org/10.1007/978-1-60761-171-4_23
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-170-7
Online ISBN: 978-1-60761-171-4
eBook Packages: MedicineMedicine (R0)